Trials / Completed
CompletedNCT05042193
A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19
A Prospective Cohort Study of Immunoglobulin G (IgG) Dynamics Against SARS-Co
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,883 (actual)
- Sponsor
- Everly Health · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to describe the longevity of IgG against SARS-CoV-2 infection or vaccination.
Detailed description
This virtual clinical study will use a prospective design, to evaluate longevity and seroprevalence of IgG against SARS-CoV-2 in approximately 800 patients as measured by Dried Blood Spots via fingerstick using the Everlywell COVID-19 Antibody Test Home Collection Kit. Participants will be followed up to 9 months at 1, 3, 6 and 9 months after enrollment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | SARS-CoV-2 | Observational |
Timeline
- Start date
- 2021-03-19
- Primary completion
- 2022-05-31
- Completion
- 2022-06-14
- First posted
- 2021-09-13
- Last updated
- 2022-06-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05042193. Inclusion in this directory is not an endorsement.